PEPGEN INC. (PEPG) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $516.34M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-117.00K; Retained Earnings (Accumulated Deficit)USD $-396.69M.
- 2026-03-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $512.91M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-59.00K; Retained Earnings (Accumulated Deficit)USD $-378.88M.
- 2025-12-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $508.54M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $11.00K; Retained Earnings (Accumulated Deficit)USD $-361.12M.
- 2025-09-30: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $505.94M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-25.00K; Retained Earnings (Accumulated Deficit)USD $-342.78M.
PEPGEN INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7.00K | $516.34M | $-117.00K | $-396.69M | $119.53M | 3 month · $3.31M |
| 2026-03-31 | $7.00K | $512.91M | $-59.00K | $-378.88M | $133.98M | 3 month · $2.85M |
| 2025-12-31 | $7.00K | $508.54M | $11.00K | $-361.12M | $147.44M | 12 month · $10.61M |
| 2025-09-30 | $7.00K | $505.94M | $-25.00K | $-342.78M | $163.14M | 3 month · $2.38M |
| 2025-06-30 | $3.00K | $395.95M | $-43.00K | $-324.75M | $71.16M | 3 month · $2.36M |
| 2025-03-31 | $3.00K | $393.49M | $-22.00K | $-301.67M | $91.81M | 3 month · $3.43M |
| 2024-12-31 | $3.00K | $390.06M | $23.00K | $-271.46M | $118.62M | 12 month · $11.46M |
| 2024-09-30 | $3.00K | $386.58M | $91.00K | $-249.22M | $137.46M | 3 month · $3.23M |
| 2024-06-30 | $3.00K | $382.95M | $-75.00K | $-227.84M | $155.04M | 3 month · $2.86M |
| 2024-03-31 | $3.00K | $378.54M | $-37.00K | $-199.50M | $179.00M | 3 month · $2.02M |
| 2023-12-31 | $2.00K | $289.87M | $34.00K | $-181.48M | $108.42M | 12 month · $7.05M |
| 2023-09-30 | $2.00K | $287.91M | $-57.00K | $-161.99M | $125.86M | 3 month · $1.94M |
| 2023-06-30 | $2.00K | $285.97M | $13.00K | $-138.70M | $147.28M | 3 month · $1.84M |
| 2023-03-31 | $2.00K | $284.04M | $-28.00K | $-119.17M | $164.84M | 3 month · $1.35M |
| 2022-12-31 | $2.00K | $282.57M | $-81.00K | $-102.86M | $179.63M | 12 month · $4.76M |
| 2022-09-30 | $2.00K | $280.99M | $-130.00K | $-87.92M | $192.94M | 3 month · $1.36M |
| 2022-06-30 | $2.00K | $279.63M | $-99.00K | $-69.31M | $210.22M | 3 month · $1.23M |
| 2022-03-31 | (m) | $2.47M | $-57.00K | $-52.00M | $-49.59M | 3 month · $815.00K |
| 2021-12-31 | (m) | $1.65M | $17.00K | $-33.75M | $-32.08M | 12 month · $1.53M |
| 2021-09-30 | (m) | (m) | (m) | (m) | $-25.61M | 3 month · $348.00K |
| 2021-06-30 | (m) | (m) | (m) | (m) | $-17.84M | 3 month · $329.00K |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-12.78M | 3 month · $188.00K |
| 2020-12-31 | (m) | (m) | (m) | (m) | $-6.36M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |